Evaluation of the efficacy and safety of QMF149 vs Mometasone in patients with asthma

• Register: EUCTR
• Last refreshed on: 25 November 2019
• Main ID: EUCTR2015-002529-21-LT
• Date of registration: 23/10/2015
• Prospective Registration: Yes
• Primary sponsor: Novartis Pharma Services AG
• Public title: Evaluation of the efficacy and safety of QMF149 vs Mometasone in patients with asthma
• Scientific title: A multicenter randomized 52 week treatment double-blind, triple dummy parallel group study to assess the efficacy and safety of QMF149 compared with mometasone furoate in patients with asthma
• Date of first enrolment: 31/12/2015
• Target sample size: 2000
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002529-21
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes; Randomised: yes; Open: no; Single blind: no; Double blind: yes; Parallel group: yes; Cross over: no; Other: yes; Other trial design description: triple-dummy; If controlled, specify comparator, Other Medicinial Product: yes; Placebo: no; Other: no; Number of treatment arms in the trial: 5
• Phase: Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no

Countries of recruitment

Bulgaria, China, Colombia, Croatia, Czech Republic, Egypt, Estonia, Germany, Guatemala, Hungary, India, Ireland, Japan, Korea, Republic of, Latvia, Lithuania, Mexico, Poland, Romania, Russian Federation, Serbia, Slovakia, South Africa, United Kingdom

Contacts

• Name: Clinical Trial Information Desk
• Affiliation: Novartis Pharma Services Inc. Representative Office

• Name: Clinical Trial Information Desk
• Affiliation: Novartis Pharma Services Inc. Representative Office

Key inclusion & exclusion criteria

Inclusion criteria:
1. Patients with a diagnosis of asthma, for a period of at least 1 year
prior to Visit 1 (Screening)
2. Patients who have used medium or high dose ICS or low dose of
LABA/ICS combinations for asthma for at least 3 months and at stable
doses for at least 1 month prior to Visit 1
3. Patients must have ACQ-7 score = 1.5 at Visit 101 and at Visit 102
(prior to double-blind treatment) and qualify for treatment with medium
or high dose LABA/ICS
4. Pre-bronchodilator = 50% FEV1 of < 85% of the predicted normal
value for the patient after withholding bronchodilators at both Visit 101
and 102,according to ATS/ERS criteria.
• Withholding period of bronchodilators prior to spirometry: SABA for =
6 hours and FDC or free combinations of ICS/LABA for = 48 hours, SAMA
for = 8 hours, xanthines >=07days.
• A one-time repeat/ re-testing of percent predicted FEV1
(prebronchodilator FEV1) is allowed at visit 101 and at visit 102.
Spacer devices are permitted for reversibility testing only.
5. Patients who demonstrate an increase in FEV1 of 12% and 200 mL
within 30 minutes after administration of 400 µg salbutamol/360 µg
albuterol (or equivalent dose) at Visit 101 All patients must perform a
reversibility test at Visit 101 If reversibility is not demonstrated at Visit
101:
- Reversibility should be repeated once
- Patients may be permitted to enter the study with historical evidence
of reversibility that was performed according to ATS/ERS guidelines
within 2 years prior to Visit
- Alternatively, patients may be permitted to enter the study with a
historical positive bronchoprovocation test that was performed within 2
years prior to Visit 1.
Are the trial subjects under 18? yes
Number of subjects for this age range: 100
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 1800
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 100

Exclusion criteria:
Exclusion Criteria:
• Patients who have smoked or inhaled tobacco products within the 6
month period prior to Visit 1, or who have a smoking history of greater
than 10 pack years. This includes or use of nicotine inhalers such as ecigarettes
at the time of Visit 1
• Patients who have had an asthma attack/exacerbation requiring
systemic steroids or hospitalization or emergency room visit within 6
weeks of Visit 1 (Screening)
• Patients who have ever required intubation for a severe asthma
at tack/exacerbation.
•Patients who have a clinical condition which is likely to be worsened by
ICS administration (e.g. glaucoma, cataract and fragility fractures) who
are according to investigator's medical judgment at risk participating in
the study).
• Patients who have had a respiratory tract infection or asthma
worsening as determined by the investigator within 4 weeks prior to
Visit 1 (Screening) or between Visit 1 and Visit 102. Patients may be
rescreened 4 weeks after recovery from their respiratory tract infection
or asthma worsening.
• Patients with a history of chronic lung diseases other than asthma,
including (but not limited to) COPD, sarcoidosis, interstitial lung disease,
cystic fibrosis, clinically significant bronchiectasis and active
tuberculosis.
• Patients with severe narcolepsy and/or insomnia.
• Patients who have a clinically significant ECG abnormality at Visit 101
(Start of Run- In epoch) and at any time between Visit 101 and
Visit 102 (including unscheduled ECG). ECG evidence of myocardial infarction at
Visit 101 (via central reader) should be clinically assessed by the
investigator with supportive documentation.
• Patients with a history of hypersensitivity tolactose, any of the study
drugs or to similar drugs within the class including untoward reactions
to sympathomimetic amines or inhaled medication or any component
thereof
• Patients who have not achieved an acceptable spirometry results at
Visit 101 in accordance with American Thoracic Society/European
Respiratory Society (ATS/ERS) criteria for acceptability and repeatability
(rescreening allowed only once).
Repeat spirometry may be allowed once in an adhoc visit if the
spirometry did not qualify due to ATS/ERS criteria. If the patient fails
the repeat assessment, the patient may be rescreened once
• Patients on Maintenance Immunotherapy (desensitization) for
allergies or less than 3 months prior to Visit 101 or patients on
Maintenance Immunotherapy for more than 3 months prior to Visit 101
but expected to change throughout
the course of the study.
•Women of child-bearing potential, defined as all women physiologically
capable of becoming pregnant, unless they are using highly effective

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]

Asthma
MedDRA version: 20.0 Level: PT Classification code 10003553 Term: Asthma System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders

Intervention(s)

Product Name: Indacaterol acetate / mometasone furoate
Product Code: QMF149
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: INDACATEROL ACETATE
Other descriptive name: INDACATEROL ACETATE
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 150-
INN or Proposed INN: MOMETASONE FUROATE
Current Sponsor code: MF
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 160-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use

Product Name: Indacaterol acetate/Mometasone furoate
Product Code: QMF149
Pharmaceutical Form: Inhalation powder, hard capsule
INN or Proposed INN: INDACATEROL ACETATE
Other descriptive name: INDACATEROL ACETATE
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 150-
INN or Proposed INN: MOMETASONE FUROATE
Current Sponsor code: MF
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 320-
Pharmaceutical form of the placebo: Inhalation powder, hard capsule
Route of administration of the placebo: Inhalation use

Trade Name: Asmanex Twisthaler
Pharmaceutical Form: Inhalation powder
INN or Proposed INN: MOMETASONE FUROATE
Current Sponsor code: MF
Other descriptive name: MOMETASONE FUROATE
Concentration unit: µg microgram(s)
Concentration type: up to

Primary Outcome(s)

Secondary Objective: To compare QMF149 150/160µg o.d. to MF 400µg o.d or QMF149 150/320µg o.d. to MF 800 µg (delivered as 400 µg b.i.d.)in terms of:
- Through FEV1 at week 52
- Pre-dose FEV1 at week 4 and 12
- FEV1, FVC and FEF over 52 weeks of treatment.
- PEF over 26 and 52 weeks
- ACQ-7 at week 4, 12, 26 and 52 weeks
- Percentage patients with MID of ACQ>=0,5 at week 26 and 52
- daily e-diary over 52 weeks
-rescue medication use over 26 and 52 weeks
- asthma exacerbation over 52 weeks
- % rescue medication free days over 26 and 52 weeks
-quality of life assessed by AQLQ-S 12 at 52 weeks
- incidence of composite endpoint of serious asthma outcomes
- Adverse event, vital signs, ECG and laboratory analysis

To compare QMF149 150/320µg with salmeterol xinafoate /fluticasone propionate 50/500µg via Accuhaler® for all the listed secondary endpoints above as well as through FEV 1 at week 26:

Main Objective: To demonstrate the superiority of either QMF149 150/160 µg delivered via Concept1 o.d. (in the evening) to MF 400 µg o.d (in the evening) delivered via Twisthaler® or QMF149 150/320 µg delivered via Concept1 o.d. (in the evening) to MF 800 µg delivered via Twisthaler® (delivered as 400 µg b.i.d.) in terms of FEV1 at 26 weeks.

Timepoint(s) of evaluation of this end point: 26 weeks

Primary end point(s): Comparison between QMF149 and Mometasone furoate in terms of FEV1.

Secondary Outcome(s)

Secondary end point(s): Comparison between QMF149 and Mometasone furoate in terms of ACQ-7

Timepoint(s) of evaluation of this end point: 26 weeks

Secondary ID(s)

CQVM149B2301

2015-002529-21-GB

Source(s) of Monetary Support

Novartis Pharma Services AG

Ethics review

Status: Approved
Approval date:
Contact: